Henoch-Schönlein purpura and meningococcal B vaccination
- K Sexton1,
- A McNicholas1,
- Y Galloway1,
- S Radke1,
- C Kieft1,
- P Stehr-Green1,
- S Reid1,
- J Neutze2,
- R Drake3
- 1Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
- 2Middlemore Hospital, Manukau, New Zealand
- 3Auckland City Hospital, Auckland, New Zealand
- Anne McNicholas, Meningococcal Vaccine Strategy, Ministry of Health, PO Box 5013, Wellington, New Zealand; anne_mcnicholas{at}moh.govt.nz
- Accepted 25 June 2008
- Published Online First 23 July 2008
Abstract
The risk of Henoch-Schönlein purpura (HSP) following vaccination with a group B meningococcal vaccine was assessed through active hospital safety monitoring. There was no increase in the relative incidence of HSP within 30 days after vaccination nor recurrence in HSP cases who received one or more further vaccine doses (re-challenge).
Footnotes
-
Competing interests: Chiron Vaccines (now Novartis Vaccines and Diagnostics S.r.l.) funded the New Zealand Ministry of Health to undertake the safety monitoring.








